SupplyLogic

Biopharmaceutical leaders who have moved beyond pilot projects with generative AI now confront a different challenge: scaling these capabilities across discovery, translational medicine, clinical development, regulatory affairs, and pharmacovigilance functions while maintaining compliance, managing risk, and demonstrating ROI. Early adopters at organizations like Pfizer, Moderna, and Roche have learned hard lessons about what works—and what fails—when operationalizing generative models in GMP, GCP, and GLP environments. This article synthesizes those insights into actionable best practices for practitioners ready to move from experimentation to enterprise deployment. Whether your organization is deploying Generative AI in Biopharma for molecular design, clinical study report automation, or ICSR narrative generation, the principles that follow will help you avoid common pitfalls, accelerate time-to-value, and build stakeholder confidence. These recommendations draw from hundreds of imp...